+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Single Cell Analysis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

  • PDF Icon


  • 110 Pages
  • May 2021
  • Region: Global
  • Mordor Intelligence
  • ID: 4557723
UP TO OFF until Dec 31st 2023
The Single Cell Analysis Market was valued at approximately USD 2,385 million in 2020 and is expected to witness a revenue of USD 5,120 million in 2026, with a CAGR of 13.10% over the forecast period.

The employment of single-cell analysis in the study of SARS-CoV2 viral infection is gaining importance during the COVID-19 pandemic, which is expected to significantly impact the studied market growth. According to the research article published in the American Journal of Physiology-Lung Cellular and Molecular Physiology, 2021, single-cell analysis through mass cytometry by time-of-flight (CyTOF) was used to study the changes in the peripheral blood mononuclear cell profiles of COVID-19 infected patients. The application of a high throughput single-cell analysis technique helps in the evaluation of the immunological responses in COVID-19 patients. Additionally, as per the research study published in Cell, 2021, single-cell RNA sequencing was applied on 284 samples of COVID-19 infected patients and created an immune landscape with 1.46 million cells, which enabled the evaluation and correlation among different peripheral immune subtype changes with varied clinical features, such as age, sex, severity, and disease stages of COVID-19. Thus, in view of the ongoing research activities, by exploring the application of the single-cell analysis technique in the SARS-CoV2 virus study, the studied market is expected to have good opportunities for growth during the pandemic era.

The growth of the single-cell analysis market is attributed to the technological advancements in single-cell analysis products, increasing investments in cancer research, and rising biotechnology and biopharmaceutical industries in recent years.

Cancer is one of the major causes of death across the world. The disease has witnessed significant growth in the past few decades and is expected to rise rapidly over the forecast period. According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide, with nearly 9,958,133 deaths due to cancers, globally. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 27.5 million new cancer cases and 16.3 million deaths worldwide. Also, circulating tumor cells are gaining increasing clinical attention since they are likely to enable the monitoring of cancer progression and adjustment of treatment. In such cases, the single-cell sequencing analysis has found its application in search of better diagnostic and prognostic biomarkers.

Additionally, in clinical diagnostics, the single-cell analysis is expected to standardize and automate workflows with valuable information for real-time monitoring of cancer and eventually new therapeutic strategies for the benefit of patients. , this aspect is expected to lead to more efficient and better analysis. Therefore, increasing investments in cancer research are considered as one of the major driving factors for the market over the forecast period. However, the high cost of the single-cell analysis instruments is expected to restrain the studied market growth.

Key Market Trends

Research Applications Segment Expected to Grow at Good Rate Over the Forecast Period

The research applications segment is expected to hold the maximum share, owing to the high prevalence of cancer, and the increasing need for stem cell research, the initiatives for early detection of chronic diseases, and increasing awareness regarding commercially available cancer diagnostics and precision medicine. In the research segment, cancer and immunology are of growing interest among the scientific communities. According to the research article published in Biomarker Research, 2020, Single-Cell analysis sequencing of circulating tumor cells is used in exploring the mechanism of drug resistance in tumor cells. Also, as per clinicaltrials.gov, as of March 2021, there were nearly 23,358 active, ongoing clinical trials in the area of oncology. This specifies the high rate of cancer research being conducted globally and as the cellular, metabolic and genetic study and evaluation of tumor cells play a vital role in the understanding of various cancers, which in turn leads to the development of effective diagnostics, therapeutics, and treatment options for cancer, the use of single-cell analysis in research application is predicted to witness significant growth.

Furthermore, Immunological studies aid in the early detection of therapeutic complications including many cancer and hematology-based indications, thereby, increase the efficiency of the treatment. According to the research article published in the Journal of Immunology Research, 2020, Single-Cell RNA Sequencing and analysis helps in studying the immune response to various infections, which can lead to the development of effective vaccines against causal organisms. Furthermore, invasion of the metabolic activities of single cells is increasing the adoption of its analytical tools, thus propelling the growth of the research segment.

North America Region Holds the Largest Market Share of Single Cell Analysis Market and is Anticipated to Follow the Same Over the Forecast Period

The large share of the North American single-cell analysis market is attributed to factors, such as increasing collaborations among prominent players, technological advancements, and expanding biotechnology and pharmaceutical industries. In recent years, several government initiatives have been launched that are supplementing the growth of the single-cell analysis market in the region. For instance, in 2018, the National Institute of Health (NIH) began the common funding named Human Biomolecular Atlas Program (HuBAP) for preparing a dataset with the molecular profiles of proteins, that can help in the identification of certain kinds of cells. This further can be used to predict the relationship and interactions between healthy and tumor samples.

Additionally, the high incidence of chronic diseases such s cancers in the region is driving the market growth. According to the Globocan 2020 report, an estimated 2,281,658 new cancer cases were diagnosed in the United States in 2020, with nearly 612,390 deaths. In 2020, The most common cancers were breast (253,465), lung (227,875), prostate (209,512), and colon (101,809) in the United States.

Also, the existence of major players in the region and new product launches is expected to boost the single-cell analysis market. For instance, in October 2020, Becton, Dickinson, and Company received US FDA's 510 (K) clearance for its BD FACSLyric Flow Cytometer with Newly Integrated BD FACSDuet Sample Preparation System. Thus, owing to the above-mentioned factors, the single-cell analysis market is expected to witness significant growth over the forecast period in North America.

Competitive Landscape

The single-cell analysis market is highly competitive with several major players. The major players of the studied market comprise Illumina, Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., Becton, Dickinson and Company, Beckman Coulter, Inc (Danaher Corporation ), Fluidigm Corporation among others. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships that help them in strengthening their market position. For instance, in April 2020, Bio-Rad Laboratories, Inc., completed the acquisition of Celsee, Inc, which is a single cell analysis solution provider, thereby expanding its product portfolio of precision medicine and single-cell analysis.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Single Cell Analysis Products
4.2.2 Increasing Investments in Cancer Research
4.2.3 Rising Biotechnology and Biopharmaceutical Industries
4.3 Market Restraints
4.3.1 High Cost of Single Cell Analysis Instruments
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Technique
5.1.1 Flow Cytometry
5.1.2 Next Generation Sequencing
5.1.3 Polymerase Chain Reaction (PCR)
5.1.4 Microscopy
5.1.5 Mass Spectrometry
5.1.6 Other Techniques
5.2 By Application
5.2.1 Research Applications
5.2.2 Medical Applications
5.3 By End User
5.3.1 Academic and Research Laboratories
5.3.2 Biotechnology and Pharmaceutical Companies
5.3.3 Hospital and Diagnostic Laboratories
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Agilent Technologies, Inc
6.1.2 Beckman Coulter Inc. (Danaher Corporation)
6.1.3 Becton, Dickinson, and Company
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Fluidigm Corporation
6.1.6 GE Healthcare (GE Company)
6.1.7 Illumina Inc.
6.1.8 Merck KGaA
6.1.9 Qiagen NV
6.1.10 Thermo Fisher Scientific Inc.
6.1.11 Promega Corporation

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Agilent Technologies, Inc
  • Beckman Coulter Inc. (Danaher Corporation)
  • Becton, Dickinson, and Company
  • Bio-Rad Laboratories Inc.
  • Fluidigm Corporation
  • GE Healthcare (GE Company)
  • Illumina Inc.
  • Merck KGaA
  • Qiagen NV
  • Thermo Fisher Scientific Inc.
  • Promega Corporation